Korro Bio, Inc.
KRRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.01 | -0.00 | 0.59 |
| FCF Yield | -22.96% | -99.98% | -119.90% | -3.20% |
| EV / EBITDA | -3.72 | 0.71 | -0.28 | -32.53 |
| Quality | ||||
| ROIC | -43.05% | -41.02% | -83.25% | -28.35% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 72.70% |
| Cash Conversion Ratio | 0.72 | 0.83 | 0.92 | 1.46 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -21.38% |
| Free Cash Flow Growth | -3.80% | -27.63% | -61.07% | 29.54% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 1.64 | 0.59 | 1.12 |
| Interest Coverage | 0.00 | 0.00 | -499.98 | -46.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -26.67 |
| Cash Conversion Cycle | 272.58 | -732.01 | -378.66 | -84.92 |